Conference abstractPublished 7 Sep 2017
HPMA Copolymer-Bound Doxorubicin as Endogenous Vaccine Substantially Increases Therapeutic Effect of Check-Point Blockade Monoclonals: Acute versus Chronic Model
Director Institute of Microbiology AS CR, Czech Republic
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
DOXHYD-HPMA is doxorubicin bound through hydrazone bond to synthetic polymeric carrier based on N-(2-hydroxypropyl)methacrylamide. It is effective anticancer polymeric prodrug with decreased side-toxicity and the ability to induce immunogenic cancer cell death releasing site-specific tumor antigen and thus acting as endogenous vaccines. We have compared chemo-immunotherapy combination treatment of EL4 T cell lymphoma and 4T1 breast carcinoma with DOXHYD-HPMA and with immune checkpoint blocking anti-CTLA-4 and anti-PD-1 MAbs either alone or in a mixture. To document the role of intestinal microbiota we use germ-free (GF) mice and GF mice monocolonized with Bifidobacterium thetaiotamicron. Acute model of disease when mice are transplanted once with a lethal dose of tumor cells was compared with chronic model where mice are injected six times every other day with a low number of tumor cells. Healthy mice treated with anti-CTLA-4 and anti-PD-1 mAbs did not show any signs of toxicity while significant co-toxicity was seen in cancer-bearing mice. Treatment with checkpoint inhibitors only exerted a very limited cancer response as no long term survivors (LTS) were recorded. On the other hand more than 60% of mice injected also with therapeutically suboptimal dose of DOXHYD-HPMA survived disease-free for more than 100 days. Those suffering from chronic model of cancer showed considerably higher proportion of PD-1+ cells in tumor microenvironment and reacted substantially better to anti-CTLA-4 or anti-PD-1 treatment than mice with the acute model Recent Publications Říhová B, Etrych T, Šírová M, Tomala J, Ulbrich K, Kovář M (2011) Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma. J Drug Target 19, 890-899. Votavova P, Tomala J, Subr V, Strohalm J, Ulbrich K, Rihova B, Kovar M (2015) Novel IL-2-Poly(HPMA)nanoconjugate based immunotherapy J Biomed Nanotechnol 11, 1662-1673. Tomalova B, Sirova M, Rossmann P, Poola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M (2016) The Structure-dependent toxicity pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukemia J Control Rel 223, 1-10. Sivák L, Šubr V, Tomala J, Říhová B, Strohalm J, Etrych T, Kovář M (2017) Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate Biomaterials 115, 65 – 80. Šírová M, Strohalm J, Chytil P, Lidický O, Tomala J, Říhová B, Etrych T (2017) The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel. J Control Rel 246, 1 – 11.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Blanka Rihova”
